TD Cowen keeps Twist Bioscience at Buy but cuts target to $137
TD Cowen kept its Buy rating on Twist Bioscience and lowered its price target by 27.9%, from $190 to $137, according to TradingView.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
TD Cowen maintained its Buy rating on Twist Bioscience shares but lowered its price target from $190 to $137, a 27.9% cut. The new target implies upside of 19.9% from the November 12 close of $114.22.
The information comes from TradingView, which cites data provided by Benzinga.
why it matters
Revisions like this reflect a change in the analyst's view of the company. Keeping the Buy rating makes the signal more moderate than negative. Investors may want to read the full analyst report and track the company's broader performance.
tags
instruments
sources
- TD Cowen maintains Twist Bioscience at Buy, lowers price target to $137 from $190 — TradingView, 13 November 2026 at 14:59 UTC
- TD Cowen maintains X-Energy at Buy, lowers price target to $25 from $35 — TradingView, 13 November 2026 at 15:01 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗